CDMO Dossier

US BIOLOGICS DRUG-SUBSTANCE SCREEN

Which US CDMO site fits your protein biologic program?

Compare published US facility scope, bioreactor scale, and supply stage across ten reviewed facilities/networks before sending a technical RFI.

All values below are vendor-reported statements from official company pages (read November 12–14, 2026); disclosed capacity never establishes open slots. Sources & dates.

SiteProcess & modality scopeDisclosed site scaleSupply stage
Lonza VacavilleVacaville
multi-product cGMP mammalian manufacturing facilityScope limits · Source ↗total capacity of 332,000Lavailability unknown · Capacity basis · Source ↗late-stage clinical (Phase 3) and commercial supplySource ↗
Lonza PortsmouthPortsmouth, New Hampshire, USA
custom production of mammalian biopharmaceuticals; GS-system for monoclonal antibodies and recombinant proteinsScope limits · Source ↗6,000L and 20,000L stainless steel bioreactorsavailability unknown · Capacity basis · Source ↗clinical and commercial manufacturingSource ↗
FUJIFILM Holly SpringsHolly Springs, North Carolina, US
Commercial-scale mammalian cell culture; monoclonal antibodies.Vendor announcement July 8, 2026; product-specific qualification still required.Source & date8 × 20,000 L mammalian reactors openedAnother 8 targeted for late FY2027; not included as current capacity.Source & dateCommercial-scale mammalian cell culture; monoclonal antibodies.Vendor announcement July 8, 2026; product-specific qualification still required.Source & date
Samsung Biologics RockvilleRockville CampusAcquired from GSK 2026-03-31
Protein-specific scope unknown in reviewed sourcesWhy unknown60,000 L ; provides 60 kL capacityavailability unknown · Capacity basis · [1] [2]Clinical and commercial biologics manufacturing (acquired from GSK Mar 31, 2026)Consolidated from 3 site statements · Exact wording · [1] [2] [3]
WuXi Biologics WorcesterWorcester, Massachusetts (plus Cranbury, New Jersey), USA
single-use biologics drug substance manufacturingprotein/mammalian expression not specified · Scope limits · Source ↗36,000L (6 x 6,000L) single-use capacity; up to 12,000L per batchavailability unknown · Capacity basis · Source ↗clinical- and commercial-scale cGMP manufacturingSource ↗
Catalent Madison & BloomingtonMadison, Wisconsin and Bloomington, Indiana, USADisclosed 2021-04-13; current operations unconfirmed
mammalian cell line technology (GPEx) and development/manufacturing for new biological entities and biosimilarsApr 2021 release; current ops unconfirmed · Scope limits · Source ↗Madison: 100 to 4,000-liter single-use (three 2x2,000L, 1,000L, 500L); Bloomington: two 2,500L stainless steel + 1,000L single-useApr 2021 release; current ops unconfirmed; availability unknown · Capacity basis · Source ↗clinical and commercial CGMP manufacturingApr 2021 release; current ops unconfirmed · Source ↗
AGC Biologics SeattleSeattle, Washington, USANamed-site mammalian equipment now documented
Seattle-specific GMP mammalian manufacturing and cell-line development.Named-site claim; molecule-specific suite fit and availability unknown.Source & date9 × 2,000 L single-use; 3,000 L stainless steelSeattle-specific equipment; simultaneous batch capacity and bookable slots unknown.Source & datenetwork-disclosed pre-clinical, clinical, and commercial programs (Seattle site-level stage confirmation pending)Source ↗
Avid Bioservices Costa MesaCosta Mesa, California, USAEarly-phase campus; Tustin handles clinical/commercial scope
CHO/HEK293 cell-line and DNA-to-IND process development.Facility development scope; manufacturing train and volume remain unknown.Source & dateBioreactor volume not published on reviewed pageHow to read capacityCosta Mesa: early phase. Tustin: clinical and commercial manufacturing.Separate campuses; confirm the transfer and manufacturing locations in the proposal.Source & date
Curia (US facilities)United States facilities (city not named on capability page)
antibodies, proteins, enzymes, and mRNA; stable mammalian cell line developmentScope limits · Source ↗Bioreactor volume not published on reviewed pageHow to read capacityIND to commercial-ready cGMP manufacturingSource ↗
Abzena BristolBristol, Pennsylvania, USABioconjugates/ADCs focus
bioconjugates and ADCs (antibodies, linker payloads, bioconjugation)Scope limits · Source ↗Bioreactor volume not published on reviewed pageHow to read capacityclinical and commercial cGMP bioconjugate useSource ↗
Editorial qualification question (not a vendor claim): Does sponsor US supply-chain / BIOSECURE procurement policy apply to your program? Applicability is unknown from saved vendor facility pages (including WuXi Biologics); confirm sponsor eligibility separately.
Open the qualification checklist → Piramal Pharma US sites (Lexington, Kentucky and Riverview, Michigan, USA (fill-finish and payload-linker; mAb DS in India)); Thermo Fisher (Patheon) site capacities and Societal CDMO remain unverified.

Explore a specific question